User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

Prospective observational study of treatment pattern, effectiveness and safety of zoledronic acid therapy beyond 24 months in patients with multiple myeloma or bone metastases from solid tumors.

Primary tabs

Van den Wyngaert, Tim [Antwerp University Hospital] Delforge, M [University Hospitals Leuven] Doyen, Chantal [UCL] Duck, L [Clinique St Pierre Ottignies] Wouters, K Wildiers, H

To study the treatment patterns, effectiveness and safety of zoledronic acid (ZOL) beyond 2 years of therapy, given the paucity of data on long-term treatment in daily clinical practice.

Document type Article de périodique (Journal article)
Access type Accès restreint
Publication date 2013
Language Anglais
Journal information "Supportive Care in Cancer" - Vol. 21, no.12, p. 3483-3490 (2013)
Peer reviewed yes
Publisher Springer ((Germany) Heidelberg)
issn 0941-4355
e-issn 1433-7339
Publication status Publié
Affiliations UCL - (MGD) Service d'hématologie
UCL - SSS/IREC/MONT - Pôle Mont Godinne
Links
  1. Raje N., Roodman G. D., Advances in the Biology and Treatment of Bone Disease in Multiple Myeloma, 10.1158/1078-0432.ccr-10-1804
  2. Weilbaecher Katherine N., Guise Theresa A., McCauley Laurie K., Cancer to bone: a fatal attraction, 10.1038/nrc3055
  3. Coleman R. E., Bisphosphonates: Clinical Experience, 10.1634/theoncologist.9-90004-14
  4. Kohno Norio, Aogi Kenjiro, Minami Hironobu, Nakamura Seigo, Asaga Taro, Iino Yuichi, Watanabe Toru, Goessl Carsten, Ohashi Yasuo, Takashima Shigemitsu, Zoledronic Acid Significantly Reduces Skeletal Complications Compared With Placebo in Japanese Women With Bone Metastases From Breast Cancer: A Randomized, Placebo-Controlled Trial, 10.1200/jco.2005.05.116
  5. Saad F., Gleason D. M., Murray R., Tchekmedyian S., Venner P., Lacombe L., Chin J. L., Vinholes J. J., Goas J. A., Zheng M., Long-Term Efficacy of Zoledronic Acid for the Prevention of Skeletal Complications in Patients With Metastatic Hormone-Refractory Prostate Cancer, 10.1093/jnci/djh141
  6. Rosen Lee S., Gordon David, Tchekmedyian Simon, Yanagihara Ronald, Hirsh Vera, Krzakowski M., Pawlicki M., de Souza Paul, Zheng Ming, Urbanowitz Gladys, Reitsma Dirk, Seaman John J., Zoledronic Acid Versus Placebo in the Treatment of Skeletal Metastases in Patients With Lung Cancer and Other Solid Tumors: A Phase III, Double-Blind, Randomized Trial—The Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group, 10.1200/jco.2003.04.105
  7. Hatoum Hind T., Lin Swu-Jane, Smith Mathew R., Barghout Victoria, Lipton Allan, Zoledronic acid and skeletal complications in patients with solid tumors and bone metastases : Analysis of a National Medical claims database, 10.1002/cncr.23775
  8. Conte P., Safety of Intravenous and Oral Bisphosphonates and Compliance With Dosing Regimens, 10.1634/theoncologist.9-90004-28
  9. Levey Andrew S., A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation, 10.7326/0003-4819-130-6-199903160-00002
  10. Cox D (1972) Regression models and life tables. J R Stat Soc Ser B 34:187–202
  11. Andersen P. K., Gill R. D., Cox's Regression Model for Counting Processes: A Large Sample Study, 10.1214/aos/1176345976
  12. Lenart Brett A., Lorich Dean G., Lane Joseph M., Atypical Fractures of the Femoral Diaphysis in Postmenopausal Women Taking Alendronate, 10.1056/nejmc0707493
  13. Chang Stephanie T., Tenforde Adam S., Grimsrud Christopher D., O'Ryan Felice S., Gonzalez Joel R., Baer David M., Chandra Malini, Lo Joan C., Atypical femur fractures among breast cancer and multiple myeloma patients receiving intravenous bisphosphonate therapy, 10.1016/j.bone.2012.05.010
  14. Bukowski Ronald, Rosen Lee S., Gordon David, Tchekmedyian Simon, Hirsh Vera, Yanagihara Ronald, Coleman Robert E., P-676 Long-term therapy with zoledronic acid is effective and safe in reducing the risk of skeletal complications in patients with bone metastases from non-small cell lung cancer, 10.1016/s0169-5002(03)92643-2
  15. Lipton A, Dewar R, Conte P, Zheng M (2004) Long-term safety of zoledronic acid for the treatment of patients with breast cancer and bone metastases. Eur J Cancer Suppl 2:142–142
  16. Saad F., Gleason D., Murray R., Venner P., Tchekmedyian S., Lacombe L., Chin J., Vinholes J., Goas J.A., Zheng M., 615 Long-term efficacy and safety of zoledronic acid in men with advanced prostate cancer and bone metastases, 10.1016/s1569-9056(04)90609-4
  17. Ali SM, Esteva FJ, Hortobagyi G, Harvey H, Seaman J, Knight R, Costa L, Lipton A (2001) Safety and efficacy of bisphosphonates beyond 24 months in cancer patients. J Clin Oncol 19:3434–3437
  18. Costa L, Alho I, Semedo M, Ribeiro J, Luis I, Quintela A, Casimiro S, Leitzel K, Ali S, Lipton A (2011) Retrospective analysis of long-term bisphosphonate therapy for patients with bone metastases — bone marker profiles and safety. In 11th International conference on cancer-induced bone disease, pp. 66: Chicago, IL
  19. Berenson James R., Hillner Bruce E., Kyle Robert A., Anderson Ken, Lipton Allan, Yee Gary C., Biermann J. Sybil, American Society of Clinical Oncology Clinical Practice Guidelines: The Role of Bisphosphonates in Multiple Myeloma, 10.1200/jco.2002.06.037
  20. Kyle Robert A., Yee Gary C., Somerfield Mark R., Flynn Patrick J., Halabi Susan, Jagannath Sundar, Orlowski Robert Z., Roodman David G., Twilde Patricia, Anderson Kenneth, American Society of Clinical Oncology 2007 Clinical Practice Guideline Update on the Role of Bisphosphonates in Multiple Myeloma, 10.1200/jco.2007.12.1269
  21. Morgan Gareth J, Davies Faith E, Gregory Walter M, Cocks Kim, Bell Sue E, Szubert Alex J, Navarro-Coy Nuria, Drayson Mark T, Owen Roger G, Feyler Sylvia, Ashcroft A John, Ross Fiona, Byrne Jennifer, Roddie Huw, Rudin Claudius, Cook Gordon, Jackson Graham H, Child J Anthony, First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial, 10.1016/s0140-6736(10)62051-x
  22. Richardson Paul G., Laubach Jacob P., Schlossman Robert L., Ghobrial Irene M., Mitsiades Constantine S., Rosenblatt Jacalyn, Mahindra Anuj, Raje Noopur, Munshi Nikhil, Anderson Kenneth C., The Medical Research Council Myeloma IX trial: the impact on treatment paradigms* : Myeloma IX: changing treatment paradigms?, 10.1111/j.1600-0609.2011.01721.x
  23. Amadori D, Aglietta M, Alessi B (2012) ZOOM: A prospective, randomized trial of zoledronic acid (ZOL; q 4 wk vs q 12 wk) for long-term treatment in patients with bone-metastatic breast cancer (BC) after 1 yr of standard ZOL treatment. J Clin Oncol 30:9005
  24. Coleman R, Wright J, Houston S (2012) Randomized trial of marker-directed versus standard schedule zoledronic acid for bone metastases from breast cancer. J Clin Oncol 30:511
  25. ClinicalTrials.gov (2012) Zoledronic Acid Treatment (Every 4 or 12 Weeks) to Prevent Skeletal Complications in Advanced Multiple Myeloma Patients (Z-MARK).
  26. ClinicalTrials.gov (2012) Efficacy and Safety of Zoledronic Acid (Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Breast Cancer
  27. Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, Apffelstaedt J, Hussein M, Coleman RE, Reitsma DJ, Seaman JJ, Chen BL, Ambros Y (2001) Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 7:377–387
  28. Saad F., Gleason D. M., Murray R., Tchekmedyian S., Venner P., Lacombe L., Chin J. L., Vinholes J. J., Goas J. A., Chen B., A Randomized, Placebo-Controlled Trial of Zoledronic Acid in Patients With Hormone-Refractory Metastatic Prostate Carcinoma, 10.1093/jnci/94.19.1458
  29. Van den Wyngaert T., Delforge M., Doyen C., Duck L., Delabaye I., Wildiers H., 3060 POSTER Renal Safety of Zoledronic Acid (ZOL) in Patients (pts) Starting ZOL Therapy and Beyond 2 Years of Treatment – a Prospective Multi-center Evaluation, 10.1016/s0959-8049(11)71133-9
  30. Stopeck Alison T., Lipton Allan, Body Jean-Jacques, Steger Guenther G., Tonkin Katia, de Boer Richard H., Lichinitser Mikhail, Fujiwara Yasuhiro, Yardley Denise A., Viniegra María, Fan Michelle, Jiang Qi, Dansey Roger, Jun Susie, Braun Ada, Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study, 10.1200/jco.2010.29.7101
  31. Henry David H., Costa Luis, Goldwasser Francois, Hirsh Vera, Hungria Vania, Prausova Jana, Scagliotti Giorgio Vittorio, Sleeboom Harm, Spencer Andrew, Vadhan-Raj Saroj, von Moos Roger, Willenbacher Wolfgang, Woll Penella J., Wang Jianming, Jiang Qi, Jun Susie, Dansey Roger, Yeh Howard, Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma, 10.1200/jco.2010.31.3304
  32. Fizazi Karim, Carducci Michael, Smith Matthew, Damião Ronaldo, Brown Janet, Karsh Lawrence, Milecki Piotr, Shore Neal, Rader Michael, Wang Huei, Jiang Qi, Tadros Sylvia, Dansey Roger, Goessl Carsten, Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study, 10.1016/s0140-6736(10)62344-6
  33. Van Poznak Catherine H., Temin Sarah, Yee Gary C., Janjan Nora A., Barlow William E., Biermann J. Sybil, Bosserman Linda D., Geoghegan Cindy, Hillner Bruce E., Theriault Richard L., Zuckerman Dan S., Von Roenn Jamie H., American Society of Clinical Oncology Executive Summary of the Clinical Practice Guideline Update on the Role of Bone-Modifying Agents in Metastatic Breast Cancer, 10.1200/jco.2010.32.5209
  34. Novartis Pharmaceuticals Corporation: Zometa® (zoledronic acid) prescribing information. East Hanover, NJ, Novartis, 2008
  35. Lebret Thierry, Mouysset Jean-Loup, Lortholary Alain, El Kouri Claude, Bastit Laurent, Ktiouet Meryem, Slimane Khemaies, Murraciole Xavier, Guérif Stéphane, Home-based zoledronic acid infusion therapy in patients with solid tumours: compliance and patient–nurse satisfaction, 10.1007/s00520-012-1705-3
  36. Migliorati Cesar Augusto, , Woo Sook-Bin, Hewson Ian, Barasch Andrei, Elting Linda S., Spijkervet Fred K. L., Brennan Michael T., A systematic review of bisphosphonate osteonecrosis (BON) in cancer, 10.1007/s00520-010-0882-1
  37. Vahtsevanos Konstantinos, Kyrgidis Athanassios, Verrou Evgenia, Katodritou Eirini, Triaridis Stefanos, Andreadis Charalampos G., Boukovinas Ioannis, Koloutsos Georgios E., Teleioudis Zisis, Kitikidou Kyriaki, Paraskevopoulos Panagiotis, Zervas Konstantinos, Antoniades Konstantinos, Longitudinal Cohort Study of Risk Factors in Cancer Patients of Bisphosphonate-Related Osteonecrosis of the Jaw, 10.1200/jco.2009.21.9584
  38. Van den Wyngaert Tim, Wouters Kristien, Huizing Manon T., Vermorken Jan B., RANK ligand inhibition in bone metastatic cancer and risk of osteonecrosis of the jaw (ONJ): non bis in idem?, 10.1007/s00520-010-1061-0
  39. Van den Wyngaert T, Huizing M, Vermorken J, Fossion E (2009) Bisphosphonate associated osteonecrosis of the jaw (ONJ) in cancer patients: conservative management techniques and consolidated guidelines. Int J Clin Dent 2:271–282
Bibliographic reference Van den Wyngaert, Tim ; Delforge, M ; Doyen, Chantal ; Duck, L ; Wouters, K ; et. al. Prospective observational study of treatment pattern, effectiveness and safety of zoledronic acid therapy beyond 24 months in patients with multiple myeloma or bone metastases from solid tumors.. In: Supportive Care in Cancer, Vol. 21, no.12, p. 3483-3490 (2013)
Permanent URL http://hdl.handle.net/2078.1/139075